Cargando…
Effects of Levosimendan on cardiac function, size and strain in heart failure patients
Levosimendan improves cardiac function in heart failure populations; however, its exact mechanism is not well defined. We analysed the short-term impact of levosimendan in heart failure patients with ischemic and non-ischemic cardiomyopathy (CMP) using multiparametric cardiac magnetic resonance (CMR...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969546/ https://www.ncbi.nlm.nih.gov/pubmed/33103224 http://dx.doi.org/10.1007/s10554-020-02077-z |
_version_ | 1783666246463520768 |
---|---|
author | Beitzke, D. Gremmel, F. Senn, D. Laggner, R. Kammerlander, A. Wielandner, A. Nolz, R. Hülsmann, M. Loewe, C. |
author_facet | Beitzke, D. Gremmel, F. Senn, D. Laggner, R. Kammerlander, A. Wielandner, A. Nolz, R. Hülsmann, M. Loewe, C. |
author_sort | Beitzke, D. |
collection | PubMed |
description | Levosimendan improves cardiac function in heart failure populations; however, its exact mechanism is not well defined. We analysed the short-term impact of levosimendan in heart failure patients with ischemic and non-ischemic cardiomyopathy (CMP) using multiparametric cardiac magnetic resonance (CMR). We identified 33 patients with ischemic or non-ischemic CMP who received two consecutive CMR scans prior to and within one week after levosimendan administration. Changes in LV ejection fraction (LVEF) and LV volumes, as well as changes in strain rates, were measured prior to and within one week after levosimendan infusion. LV scarring, based on late gadolinium enhancement (LGE), was correlated to changes in LV size and strain rates. Both LV endiastolic (EDV) and endsystolic volumes (ESV) significantly decreased (EDV: p=0,001; ESV: p=0,002) after levosimendan administration, with no significant impact on LVEF (p=0.41), cardiac output (p=0.61), and strain rates. Subgroup analyses of ischemic or non-ischemic CMP showed no significant differences between the groups in terms of short-term LV reverse remodeling. The presence and extent of scarring in LGE did not correlate with changes in LV size and strain rates. CMR is able to monitor cardiac effects of levosimendan infusion. Short-term follow-up of a single levosimendan infusion using CMR shows a significant decrease in LV size, but no impact on LVEF or strain measurements. There was no difference between patients with ischemic or non-ischemic CMP. Quantification of LV scarring in CMR is not able to predict changes in LV size and strain rates in response to levosimendan. |
format | Online Article Text |
id | pubmed-7969546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-79695462021-04-05 Effects of Levosimendan on cardiac function, size and strain in heart failure patients Beitzke, D. Gremmel, F. Senn, D. Laggner, R. Kammerlander, A. Wielandner, A. Nolz, R. Hülsmann, M. Loewe, C. Int J Cardiovasc Imaging Original Paper Levosimendan improves cardiac function in heart failure populations; however, its exact mechanism is not well defined. We analysed the short-term impact of levosimendan in heart failure patients with ischemic and non-ischemic cardiomyopathy (CMP) using multiparametric cardiac magnetic resonance (CMR). We identified 33 patients with ischemic or non-ischemic CMP who received two consecutive CMR scans prior to and within one week after levosimendan administration. Changes in LV ejection fraction (LVEF) and LV volumes, as well as changes in strain rates, were measured prior to and within one week after levosimendan infusion. LV scarring, based on late gadolinium enhancement (LGE), was correlated to changes in LV size and strain rates. Both LV endiastolic (EDV) and endsystolic volumes (ESV) significantly decreased (EDV: p=0,001; ESV: p=0,002) after levosimendan administration, with no significant impact on LVEF (p=0.41), cardiac output (p=0.61), and strain rates. Subgroup analyses of ischemic or non-ischemic CMP showed no significant differences between the groups in terms of short-term LV reverse remodeling. The presence and extent of scarring in LGE did not correlate with changes in LV size and strain rates. CMR is able to monitor cardiac effects of levosimendan infusion. Short-term follow-up of a single levosimendan infusion using CMR shows a significant decrease in LV size, but no impact on LVEF or strain measurements. There was no difference between patients with ischemic or non-ischemic CMP. Quantification of LV scarring in CMR is not able to predict changes in LV size and strain rates in response to levosimendan. Springer Netherlands 2020-10-24 2021 /pmc/articles/PMC7969546/ /pubmed/33103224 http://dx.doi.org/10.1007/s10554-020-02077-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Paper Beitzke, D. Gremmel, F. Senn, D. Laggner, R. Kammerlander, A. Wielandner, A. Nolz, R. Hülsmann, M. Loewe, C. Effects of Levosimendan on cardiac function, size and strain in heart failure patients |
title | Effects of Levosimendan on cardiac function, size and strain in heart failure patients |
title_full | Effects of Levosimendan on cardiac function, size and strain in heart failure patients |
title_fullStr | Effects of Levosimendan on cardiac function, size and strain in heart failure patients |
title_full_unstemmed | Effects of Levosimendan on cardiac function, size and strain in heart failure patients |
title_short | Effects of Levosimendan on cardiac function, size and strain in heart failure patients |
title_sort | effects of levosimendan on cardiac function, size and strain in heart failure patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969546/ https://www.ncbi.nlm.nih.gov/pubmed/33103224 http://dx.doi.org/10.1007/s10554-020-02077-z |
work_keys_str_mv | AT beitzked effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients AT gremmelf effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients AT sennd effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients AT laggnerr effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients AT kammerlandera effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients AT wielandnera effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients AT nolzr effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients AT hulsmannm effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients AT loewec effectsoflevosimendanoncardiacfunctionsizeandstraininheartfailurepatients |